Overview

Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)

Status:
Completed

Trial end date:
2019-07-17

Target enrollment:

Participant gender:

Summary

This is a pilot randomized, double-blind, active-controlled, 2-treatment, crossover study to evaluate the PK, user experience and abuse liability of manipulated ADAIR compared to a manipulated commercially-available d-amphetamine sulfate IR formulation administered intranasally in non-dependent recreational stimulant users. The study is comprised of 4 phases: Screening, Qualification, Treatment, and Follow-up/Early Termination.

Phase:

Phase 1

Details

Lead Sponsor:

Vallon Pharmaceuticals, Inc.

Treatments:

Amphetamine
Dextroamphetamine